TICKERNERD
Menu
CALCCALCHealthcare · Biotechnology

CALC Stock Forecast: CalciMedica, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.75
−24.73% on the day

The 2 Wall Street analysts covering CalciMedica, Inc. hold a median 12-month price target of $11 — +1295.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$15.8M
Ticker Nerd rank
36 / 100
Median analyst target
$11
Analysts covering
2
Total return, dividends reinvested
1W
+7.1%
1M
−22.0%
YTD
−88.6%
1Y
−74.4%
From 52W high
−88.8%
From 52W low
+48.5%
$0.51
$6.74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CALC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CalciMedica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Revisions
73
Issuance
69
Growth
59
Volatility
52
Accruals
27
Value
22
Quality
12
Momentum
11

Size (85): Smaller than most of the companies we track.

Momentum (11): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own CalciMedica, Inc. — and when they’d sell — is the membership.

Wall Street

CALC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CALC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26CALCHigh $15Median $11Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $6Median $11High $15

The green dot is the last close — the median target sits +1295.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Mar 2026OppenheimerMaintainsOutperform$20 → $10
29 Jan 2026HC Wainwright & Co.DowngradeNeutral—
15 May 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024LUCID CAPITAL MARKETSInitiatesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
10 July 2024OppenheimerMaintainsOutperform—
9 July 2024HC Wainwright & Co.ReiteratesBuy—
27 June 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
1 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Apr 2024OppenheimerMaintainsOutperform—
13 Mar 2024HC Wainwright & Co.ReiteratesBuy—
16 Feb 2024JonesTradingInitiatesBuy—
13 Feb 2024HC Wainwright & Co.ReiteratesBuy—
29 Jan 2024HC Wainwright & Co.InitiatesBuy—
13 Nov 2023OppenheimerReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CALC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

CalciMedica, Inc. (CALC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
−14.3×

Cheaper than 98% of US stocks

EV / EBITDA
−0.6×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−399.5%

Higher than 3% of US stocks

Return on assets
−81.9%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CALC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CALCCalciMedica, Inc.$15.8M
36
YARWYarrow Bioscience, Inc.$30.1M
34
ESLAEstrella Immunopharma, Inc.$30.0M
19
SERSerina Therapeutics, Inc.$29.8M
15
BCTXBriaCell Therapeutics Corp.$29.6M
7
LTRNLantern Pharma, Inc.$33.6M
68
NTRBNutriband, Inc.$34.3M
17
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CALC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CALC news & analysis

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

PRNewsWire · 29 July 2026positive

CalciMedica announced that the FDA has aligned with the company on the Phase 2b trial design and endpoints for Auxora in acute pancreatitis, including new-onset severe respiratory failure as the primary endpoint and a patient enrichment strategy using elevated lactate dehydrogenase (LDH).

Why it matters — This FDA alignment moves Auxora's registration program forward and establishes the first potential registrational endpoints for acute pancreatitis, a key regulatory milestone for the company.

FAQ

Frequently asked questions about CALC stock

What is the CALC stock price forecast for 2026-2027?

The 2 Wall Street analysts covering CalciMedica, Inc. have a median 12-month price target of $11, with estimates ranging from $6 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CALC stock a buy right now?

Of the 2 analysts covering CalciMedica, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CalciMedica, Inc. 36 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CALC?

As at 1 Aug 2026, CalciMedica, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will CALC stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1295.0% from the last close, and Ticker Nerd's factor model ranks CalciMedica, Inc. 36 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CALC stock forecast for 2030?

No analyst covering CalciMedica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CALC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $15 over the next 12 months.

How has CALC stock performed over the past year?

CalciMedica, Inc. returned -74.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CalciMedica, Inc. do?

Calcimedica Inc. is a biopharmaceutical company focused on developing new therapies that target calcium-release-activated calcium (CRAC) channels.

What is the latest news on CALC?

The most recent item we track (PRNewsWire, 29 July 2026): "CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints". CalciMedica announced that the FDA has aligned with the company on the Phase 2b trial design and endpoints for Auxora in acute pancreatitis, including new-onset severe respiratory failure as the primary endpoint and a patient enrichment strategy using elevated lactate dehydrogenase (LDH).

Company

About CalciMedica, Inc.

Calcimedica Inc. is a biopharmaceutical company focused on developing new therapies that target calcium-release-activated calcium (CRAC) channels. These channels play a crucial role in calcium-mediated signaling in cells, essential for the body's immune response. Calcimedica's primary objective is to innovate treatments for inflammatory diseases such as acute pancreatitis and acute lung injuries, where these channels have shown significant therapeutic potential. The company's research and development efforts are geared towards creating targeted CRAC channel inhibitors that can modulate the immune system effectively. Calcimedica operates at the intersection of biotechnology and healthcare, contributing to advancements in managing severe inflammatory conditions. Its progress impacts both the biotech sector and the broader pharmaceutical landscape, highlighting the importance of targeted molecular therapies. As a specialized entity in the biopharmaceutical industry, Calcimedica plays a crucial role in the continuous effort to bring cutting-edge solutions to medical challenges that still present significant unmet needs.

CEO Dr. A. Rachel Leheny Ph.D. · 16 employees · United States · https://calcimedica.com